Drug addiction is a complex, chronic relapsing illness characterized by compulsive drug use. It is a serious public health issue that affects the individual, family, and communities at large. It is one of the most difficult forms of addiction to overcome and is associated with a wide variety of short-term and long-term physical and mental health consequences. Drug addiction is a form of substance-use disorder which occurs when a person develops an intense craving and compulsion to take drugs. It is a progressive illness which makes it difficult to stop using drugs, even when the individual knows the negative consequences of their drug use. Drug addiction also changes the structure and functioning of the brain affecting psychology and behaviour. It is a complex chronic illness, with social, genetic, and environmental determinants. Once an individual becomes addicted to drugs, their body starts to develop a tolerance to the drug, meaning they need higher amounts over time to produce the same effect. The individual may also experience severe physical and psychological withdrawal symptoms, when the drug is stopped abruptly, making it hard to maintain abstinence from drugs. Treatment for drug addiction is an essential part of recovery. Medications such as methadone or buprenorphine, as well as comprehensive behavioral therapy, have been shown to be effective in treating drug addiction. Treatment should focus on the individual, not just their drug abuse. Treatment should be tailored to the individual needs, addressing the motivations for drug use and addressing the psychological and social issues associated with substance use. Life-long recovery from drug addiction is possible, but is dependent on the individual's commitment to making long-term changes to their lifestyle and behavior.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom